Resumen de acción SIGA
SIGA Technologies, Inc. es una empresa farmacéutica en fase comercial centrada en los mercados relacionados con la seguridad sanitaria en Estados Unidos.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 5/6 |
| Financial Health | 6/6 |
| Dividends | 3/6 |
Recompensas
Análisis de riesgos
Competidores de SIGA Technologies, Inc.
Historial de precios y rendimiento
| Historical stock prices | |
|---|---|
| Current Share Price | US$8.83 |
| 52 Week High | US$10.00 |
| 52 Week Low | US$4.22 |
| Beta | 0.97 |
| 1 Month Change | 3.15% |
| 3 Month Change | 78.74% |
| 1 Year Change | 51.72% |
| 3 Year Change | 21.29% |
| 5 Year Change | 58.24% |
| Change since IPO | 68.19% |
Noticias y actualizaciones recientes
SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Rockets 64% But Many Are Still Ignoring The Company
Mar 31
Siga Technologies: Preparing For A Contingency If Tomorrow Comes
Mar 25Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality
Mar 19Recent updates
SIGA Technologies, Inc. (NASDAQ:SIGA) Stock Rockets 64% But Many Are Still Ignoring The Company
Mar 31Siga Technologies: Preparing For A Contingency If Tomorrow Comes
Mar 25Shareholders Can Be Confident That SIGA Technologies' (NASDAQ:SIGA) Earnings Are High Quality
Mar 19The Price Is Right For SIGA Technologies, Inc. (NASDAQ:SIGA)
Feb 15Do SIGA Technologies' (NASDAQ:SIGA) Earnings Warrant Your Attention?
Jan 13SIGA Technologies secures new contract awarded to procure up to $10.7M of TPOXX
Sep 29Siga monkeypox therapy undergoes NIH-led late-stage trial
Sep 09Scientists behind key COVID study run monkeypox trial for SIGA therapy
Aug 23SIGA to activate first trial sites for monkeypox therapy in U.K. next week – Bloomberg
Aug 17Estimating The Fair Value Of SIGA Technologies, Inc. (NASDAQ:SIGA)
Aug 12SIGA to deliver $26M of monkeypox therapy to U.S. in 2023 after option exercise
Aug 09SIGA Technologies: Unjustified Selloff, Loading The Boat, Best Monkeypox Play
Aug 01SIGA Technologies: Buy Monkeypox
Jul 25Siga Technologies receives approval from UK for tecovirimat
Jul 08SIGA Technologies: Solid Business With Means To Address Monkeypox Outbreak
May 27SIGA Technologies: There's An Assured Market For A Smallpox Vaccine
Dec 12It's Probably Less Likely That SIGA Technologies, Inc.'s (NASDAQ:SIGA) CEO Will See A Huge Pay Rise This Year
Jun 08SIGA Technologies: Biodefense Pharma Unlocks New Value Abroad For TPOXX
Apr 28Introducing SIGA Technologies (NASDAQ:SIGA), The Stock That Soared 880% In The Last Five Years
Feb 22We're Not So Sure You Should Rely on SIGA Technologies' (NASDAQ:SIGA) Statutory Earnings
Feb 02SIGA Technologies +4% AH, announces Canada contract to purchase up to ~$33M of oral TPOXX
Jan 13Is SIGA Technologies, Inc.'s (NASDAQ:SIGA) Latest Stock Performance Being Led By Its Strong Fundamentals?
Jan 12
Read This Before Buying SIGA Technologies, Inc. (NASDAQ:SIGA) Shares
Dec 22Getting In Cheap On SIGA Technologies, Inc. (NASDAQ:SIGA) Is Unlikely
Dec 04Rentabilidad de los accionistas
| SIGA | US Pharmaceuticals | Mercado US | |
|---|---|---|---|
| 7D | 5.7% | -0.01% | 2.0% |
| 1Y | 51.7% | 9.5% | 22.3% |
Rentabilidad vs. Industria: SIGA superó al sector US Pharmaceuticals , que obtuvo un rendimiento del 9.5% el año pasado.
Rentabilidad vs. Mercado: SIGA superó al mercado US, que obtuvo un rendimiento del 19.3% el año pasado.
Volatilidad de los precios
| SIGA volatility | |
|---|---|
| SIGA Average Weekly Movement | 9.9% |
| Pharmaceuticals Industry Average Movement | 9.7% |
| Market Average Movement | 6.0% |
| 10% most volatile stocks in US Market | 16.6% |
| 10% least volatile stocks in US Market | 3.0% |
Precio estable de las acciones: El precio de las acciones de SIGA ha sido volátil en los últimos 3 meses.
Volatilidad a lo largo del tiempo: La volatilidad semanal de SIGA (10%) se ha mantenido estable durante el año pasado.
Acerca de la empresa
| Fundada | Empleados | CEO | Página web |
|---|---|---|---|
| 1995 | 45 | Diem Nguyen | www.siga.com |
SIGA Technologies, Inc. es una empresa farmacéutica en fase comercial centrada en los mercados relacionados con la seguridad sanitaria en Estados Unidos. Su principal producto es TPOXX, un medicamento antivírico de formulación oral para el tratamiento de la viruela humana causada por el virus de la viruela. La empresa se constituyó en 1995 y tiene su sede en Nueva York.
Resumen de fundamentos de SIGA Technologies, Inc.
| Estadísticas fundamentales de SIGA | |
|---|---|
| Capitalización bursátil | US$625.17m |
| Beneficios(TTM) | US$68.07m |
| Ingresos (TTM) | US$139.92m |
9.2x
Ratio precio-beneficio (PE)4.5x
Ratio precio-ventas (PS)¿Está SIGA sobrevalorada?
Ver valor justo y análisis de valoraciónBeneficios e Ingresos
| Cuenta de resultados (TTM) de SIGA | |
|---|---|
| Ingresos | US$139.92m |
| Coste de los ingresos | US$34.25m |
| Beneficio bruto | US$105.66m |
| Otros gastos | US$37.60m |
| Beneficios | US$68.07m |
Últimos beneficios comunicados
Dec 31, 2023
Próxima fecha de beneficios
n/a
| Beneficios por acción (BPA) | 0.96 |
| Margen bruto | 75.52% |
| Margen de beneficio neto | 48.65% |
| Ratio deuda/patrimonio | 0% |
¿Cómo se ha desempeñado SIGA a largo plazo?
Ver rendimiento histórico y comparativa